France-based medical device company Qaelon Medical announced on Wednesday that it has named Liam Burns as its new chief executive officer.

In the new role, Burns is to head the pioneering development and commercialisation of the company's proprietary new insufflation platform that is claimed to provide fast, reliable detection of surgical leaks and GI perforations that today's visual test methods can miss.

Burns has more than 25 years of experience improving the way surgery is performed for cancer, GI disease and metabolic health. During that period, he was responsible for building and heading cross-functional teams, driving product development, and commercialising innovative technologies for companies such as Ethicon (JNJ), Conmed (Airseal) and Dextera (acquired by B Braun Aesculap).

Lee Swanstrom, Qaelon Medical MD and President, said, 'We are delighted to welcome Liam as the leader of the Qaelon team. His extensive experience in minimally invasive surgery and commercializing new technologies will be a critical asset as we bring our life-saving technology to the laparoscopic, robotic and endoscopic surgical markets. As an experienced medical device leader, his insight and direction will be instrumental in establishing Qaelon as the new standard of care for insufflation and surgical leak detection.'